Aquestive Therapeutics, Inc.
AQSTHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeAquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company carries a $493.0M market cap, placing it firmly in the small-cap category. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older.
Market Cap
$493.0M
Beta
1.50
P/E (TTM)
—
P/E (Fwd)
-8.73
EPS (TTM)
$-0.61
EPS (Fwd)
$-0.45
ROE
—
ROA
-28.7%
Cash
$110.7M
Total Debt
$43.6M
Free CF
-$25.7M
52W Change
15.3%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $110.7M in cash comfortably exceeding the $43.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$25.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has been relatively flat, moving from $47.7M (2022) to $44.5M (2025).
With cash comfortably exceeding debt, AQST has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Aquestive Therapeutics, Inc. and its sector.